证券简称：何氏眼科 证券代码：301103 （草案）摘要 二零二五年九月 2025 年限制性股票激励计划（草案）摘要 声明 本公司及全体董事保证本激励计划草案及其摘要不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 本公司所有激励对象承诺：如因公司信息披露文件中有虚假记载、误导性陈 述或重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或重大遗漏后，将因本激励计划所 获得的全部利益返还公司。 1 2025 年限制性股票激励计划（草案）摘要 辽宁何氏眼科医院集团股份有限公司 2025 年限制性股票激励计划 特别提示 一、辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"、"本公司" 或"公司"）2025 年限制性股票激励计划（草案）系依据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—— 业务办理》及其他有关法律、法规及规范性文件和《辽宁何氏眼科医院集团股份 有限公司章程》制订。 二、 ...

证券简称：何氏眼科 证券代码：301103 辽宁何氏眼科医院集团股份有限公司 2025 年限制性股票激励计划 声明 本公司及全体董事保证本激励计划草案及其摘要不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 本公司所有激励对象承诺：如因公司信息披露文件中有虚假记载、误导性陈 述或重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或重大遗漏后，将因本激励计划所 获得的全部利益返还公司。 1 2025 年限制性股票激励计划（草案） 特别提示 一、辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"、"本公司" 或"公司"）2025 年限制性股票激励计划（草案）系依据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—— 业务办理》及其他有关法律、法规及规范性文件和《辽宁何氏眼科医院集团股份 有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）。股票 来源为辽宁何氏 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Core Viewpoint - He Eye Hospital's recent investment in the establishment of an industrial investment fund is strategically focused on enhancing its core business in eye health and exploring quality investment opportunities in the upstream and downstream of the industry chain as well as in emerging fields of new-generation healthcare [1] Group 1 - The company aims to strategically focus on its core business of eye health [1] - The investment is intended to facilitate professional division of labor within the industry [1] - The company is seeking quality investment targets in related emerging healthcare sectors [1]

（编辑 姚尧） 证券日报网讯 何氏眼科9月17日在互动平台回答投资者提问时表示，公司是一家由"专家办院"，集医、 教、研于一体眼健康服务机构，创立以来秉承"贡献社会 患者信赖 共同发展"的经营理念，为大众提供 全生命周期的眼健康服务。公司深耕眼健康领域二十余年，拥有丰富的眼健康服务经验、成熟的医师培 养体系、良好的患者口碑及完善的三级眼健康医疗服务模式，以打造"智慧光明城"为目标，通过精准医 疗和智慧医疗赋能，为患者全面开启数字化、全场景、全生命周期眼健康管理的服务新模式，为患者提 供精准、便捷的眼科健康管理，推动眼科医疗服务向智能化、个性化的方向发展。 ...

Core Points - The company, He Eye Hospital Group, announced the release of lock-up shares totaling 74,936,340 shares, which accounts for 47.4201% of the total share capital [2] - The lock-up period for these shares was originally set for 36 months from the date of the initial public offering but has been extended by an additional 6 months due to the stock price conditions [2] - The new circulation date for the released shares is set for September 22, 2025 [2]

中原证券股份有限公司关于 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕126 号）同意注册，公司首 次公开发行人民币普通股（A 股）股票 3,050.00 万股，并于 2022 年 3 月 22 日在 深圳证券交易所创业板上市。公司首次公开发行前总股本 91,058,824 股，首次公 开发行股票完成后总股本为 121,558,824 股，其中有限售条件流通股数量为 92,632,517 股，占发行后总股本的 76.20%，无限售条件流通股数量为 28,926,307 股，占发行后总股本的 23.80%。 2022 年 5 月 19 日，公司 2021 年度股东大会审议通过《关于 2021 年度利润 分配及资本公积金转增股本预案的议案》，以公司总股本 121,558,824 股为基数， 向全体股东每 10 股派发现金股利 6 元（含税），共计分配现金股利 72,935,294.40 元，剩余未分配利润结转以后年度；以资本公积金转增股本的方式向全体股东每 10 股转增 3 股，转增 36,467,647 ...

证券代码： 301103 证券简称：何氏眼科 公告编号：2025-034 辽宁何氏眼科医院集团股份有限公司 关于首次公开发行前已发行股份解除限售并上市流通 的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为辽宁何氏眼科医院集团股份有限公司（以下简称 "公司"）首次公开发行前已发行的股份。本次解除限售股东户数共计 7 户，解除 限售股份数量为 74,936,340 股，占公司总股本的 47.4201%，限售期为自公司首 次公开发行股票并上市之日起 36 个月。因公司股票发行上市后 6 个月内连续 20 个交易日的收盘价均低于发行价，触发锁定期延长承诺的履行条件，该 7 名股东 的股份锁定期延长 6 个月至 2025 年 9 月 21 日。 2、本次解除限售股份的上市流通日期为 2025 年 9 月 22 日（星期一）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕126 号）同意注册，公司首 次公开发行人民币 ...

Core Points - The company held its first extraordinary general meeting of shareholders in 2025 on September 15, 2025, with no proposals for increase, change, or rejection [1][3] - The meeting was conducted both in-person and via online voting, ensuring compliance with relevant laws and regulations [2][4] Meeting Details - The meeting was convened by the company's board of directors and was presided over by Director Zhou Jinfeng [3][6] - The in-person meeting took place at 14:00 on September 15, 2025, at a specified location in Shenyang, with online voting available throughout the day [5][6] - A total of 55 shareholders participated, representing 73,359,851 shares, which is 47.2364% of the total voting shares [8] Voting Results - The following proposals were approved during the meeting: - The proposal to reappoint the auditing firm for the 2025 fiscal year received 99.7930% approval [11] - The proposal to amend the company's articles of association was approved with 99.7924% [13] - Various governance rules were revised and approved, including the rules for shareholder meetings and board meetings, with approval rates exceeding 99.79% [16][20][23] - The proposal to use part of the raised funds to acquire 70.65% of the shares of a subsidiary was approved with 99.8024% [30] Legal Opinions - The meeting was witnessed by lawyers from a reputable law firm, confirming that the procedures followed were in accordance with legal requirements [32] Additional Announcements - The company announced the resignation of non-independent director Li Pingping and the election of Li Lijuan as a representative director from the employees [36][37]

Core Viewpoint - He Eye Hospital (301103) announced the election of Li Lijuan as the employee representative director of the third board of directors during the employee representative meeting held on September 15, 2025 [1] Company Summary - He Eye Hospital held an employee representative meeting on September 15, 2025 [1] - Li Lijuan was elected as the employee representative director [1]